NPI 1164410650: Open Payments
NPI 1164410650. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,354 in 64 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $452 · 2025 $1,354
Food & beverage: $1,354
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $272 |
| PROTEGA PHARMACEUTIALS INC | 4 | $226 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $178 |
| Novartis Pharmaceuticals Corporation | 7 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $106 |
| PFIZER INC. | 4 | $87 |
| ARGENX US, INC. | 2 | $67 |
| Eisai Inc. | 2 | $48 |
| Medtronic, Inc. | 2 | $37 |
| Biogen, Inc. | 1 | $28 |
Products named: ROXYBOND, UBRELVY, RELISTOR, KESIMPTA, HYQVIA, QULIPTA, Leqembi, ZAVZPRET.
